{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:46:40Z","timestamp":1788536800633,"version":"build-2803163510"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world evidence on dinutuximab beta for high-risk neuroblastoma (NB) in the Chinese pediatric patients remains limited. This study evaluated clinical efficacy and safety of dinutuximab beta as first-line maintenance therapy in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed pediatric patients newly diagnosed with high-risk NB who after induction and consolidation therapy, received dinutuximab beta combined with granulocyte-macrophage colony-stimulating factor and isotretinoin, with or without chemotherapy. The primary outcome was objective response rate (ORR); secondary outcomes included 1- and 2-year event-free survival (EFS) and overall survival (OS) rates, and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight patients were included, with a median age of 56 months (range 27-113) at the initiation of dinutuximab beta. Prior to immunotherapy, 14 patients had achieved complete response (CR) and 14 partial response (PR). Among those with CR, the CR maintenance rate was 78.6% (11\/14). In patients with PR, the ORR at the end of treatment (EOT) was 64.3% (9\/14). Stratified by treatment modality, PR patients receiving dinutuximab beta with chemotherapy had a higher ORR than those treated with dinutuximab beta alone at EOT [70.0% (7\/10) vs. 50.0% (2\/4)]. Regarding autologous stem cell transplantation (ASCT) status, all 3 patients who underwent ASCT achieved CR at EOT (ORR: 100%), whereas the ORR among patients without ASCT was 54.5% (6\/11). The overall 1-year and 2-year EFS rates were 88.2% [95% confidence interval (CI), 67.4\u201396.1%)] and 72.4% (95% CI, 41.4\u201388.8%), respectively; 1-year and 2-year OS rates were both 95.8% (95% CI, 73.9\u201399.4%). Adverse events (AEs) were common but mostly mild to moderate in severity. Grade 3 or higher AEs occurred predominantly in patients who received combination chemotherapy, including fever, neutropenia, and thrombocytopenia. Pain was effectively managed with most patients requiring only minimal oral morphine (0.01\u20130.05 mg\/kg\/d) during cycles 3\u20135.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dinutuximab beta shows favorable efficacy for pediatric patients with high-risk NB. Patients treated with prior ASCT or combined with chemotherapy showed trends toward improved response rates and survival outcomes, although optimal treatment regimens required further investigation. AEs are generally manageable, and the use of standardized pain assessment combined with multimodal analgesia has enabled a substantial reduction in morphine exposure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1765578","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:22:50Z","timestamp":1770614570000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of dinutuximab beta combined with GM-CSF and isotretinoin \u00b1 chemotherapy as first-line maintenance treatment for pediatric high-risk neuroblastoma in China"],"prefix":"10.3389","volume":"16","author":[{"given":"Wen","family":"Zhao","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyi","family":"Yang","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qin","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Fan","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Jin","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Duan","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xisi","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunying","family":"Cui","sequence":"additional","affiliation":[{"name":"School of Pharmaceutical Sciences, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Su","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Pediatric Oncology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health","place":["Beijing, China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","place":["Beijing, China"]},{"name":"National Key Clinical Discipline of Pediatric Oncology, Key Laboratory of Major Diseases in Children, Ministry of Education","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2019.00009","article-title":"Neuroblastoma\u2014a neural crest derived embryonal Malignancy","volume":"12","author":"Johnsen","year":"2019","journal-title":"Front Mol Neurosci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01541-0","article-title":"Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study","volume":"400","author":"Ni","year":"2022","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00643-z","article-title":"Advancing therapy for neuroblastoma","volume":"19","author":"Qiu","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007798","article-title":"Neuroblastoma: an ongoing cold front for cancer immunotherapy","volume":"11","author":"Kennedy","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.571","article-title":"Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children\u2019s Oncology Group","volume":"23","author":"London","year":"2005","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41467-025-56619-x","article-title":"The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial","volume":"16","author":"Mora","year":"2025","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ejca.2019.02.003","article-title":"Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children\u2019s Oncology Group (COG)","volume":"112","author":"Navin","year":"2019","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00058-7","article-title":"Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group \u2018Survey\u2019 1982-1992","volume":"36","author":"Cotterill","year":"2000","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4648","article-title":"Advances in risk classification and treatment strategies for neuroblastoma","volume":"33","author":"Pinto","year":"2015","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/ped4.12214","article-title":"Treatment and outcomes of 1041 pediatric patients with neuroblastoma who received multidisciplinary care in China","volume":"4","author":"Su","year":"2020","journal-title":"Pediatr Invest"},{"key":"B11","doi-asserted-by":"publisher","first-page":"116093","DOI":"10.1016\/j.ejca.2025.116093","article-title":"Paediatric strategy forum for medicinal product development of agents targeting GD2 ganglioside in children and adolescents with cancer","volume":"231","author":"DuBois","year":"2025","journal-title":"Eur J Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.3390\/cancers16162865","article-title":"Current knowledge and perspectives of immunotherapies for neuroblastoma","volume":"16","author":"Mao","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30578-3","article-title":"Interleukin 2 with anti-GD2 antibody ch14.18\/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1\/SIOPEN): a multicentre, randomised, phase 3 trial","volume":"19","author":"Ladenstein","year":"2018","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/19420862.2017.1402997","article-title":"Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18\/CHO","volume":"10","author":"Mueller","year":"2018","journal-title":"MAbs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn421158-20211227-00638","article-title":"Expert consensus on diagnosing and treating of neuroblastoma in children: CCCG\u2043NB\u20432021","volume":"43","year":"2022","journal-title":"Chin J Pediatr Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1055\/a-2556-4302","article-title":"GPOH guidelines for diagnosis and first-line treatment of patients with neuroblastic tumors, update 2025","volume":"237","author":"Simon","year":"2025","journal-title":"Klin Padiatr"},{"key":"B18","unstructured":"Neuroblastoma. NCCN clinical practice guidelines in oncology. version 1.2025\n          \n          \n          Plymouth Meeting, PA\n          National Comprehensive Cancer Network\n          \n          2025"},{"key":"B19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3390\/cancers12020309","article-title":"Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1)","volume":"12","author":"Ladenstein","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2008.16.6876","article-title":"The international neuroblastoma risk group (INRG) staging system: An INRG task force report","volume":"27","author":"Monclair","year":"2009","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.0177","article-title":"Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12887-025-05568-x","article-title":"A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China","volume":"25","author":"Yu","year":"2025","journal-title":"BMC Pediatr"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1082771","article-title":"Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma","volume":"13","author":"Wieczorek","year":"2023","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3892\/ol.2025.15438","article-title":"Extended cycles of anti-GD2 antibody dinutuximab beta treatment combined with chemotherapy in patients with relapsed or refractory neuroblastoma: A retrospective study","volume":"31","author":"Gong","year":"2025","journal-title":"Oncol Lett"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1041443","article-title":"Dinutuximab beta plus conventional chemotherapy for relapsed\/refractory high-risk neuroblastoma: A single-center experience","volume":"12","author":"Olgun","year":"2022","journal-title":"Front Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01868","article-title":"Dinutuximab beta added to temozolomide-based chemotherapy for children with relapsed and refractory neuroblastoma: results of the ITCC-SIOPEN BEACON immuno phase II trial","volume":"44","author":"Gray","year":"2026","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.12372\/jcp.2022.21e1685","article-title":"Expert consensus on the clinical application of GD2 antibody dinutuximab beta for the treatment of neuroblastoma (2021 edition)","volume":"40","year":"2022","journal-title":"J Chin Pediatr"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01033-4","article-title":"Survival benefit of myeloablative therapy with autologous stem cell transplantation in high-risk neuroblastoma: a systematic literature review","volume":"19","author":"\u017bebrowska","year":"2024","journal-title":"Target Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1673-5323.2021.05.010","article-title":"Prognostic implications of minimal residual disease in neuroblastoma patients: a retrospective single-center analysis","volume":"5","author":"Feng","year":"2021","journal-title":"J Chin Pediatr Blood Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s11523-022-00930-w","article-title":"Recent evidence-based clinical guide for the use of dinutuximab beta in pediatric patients with neuroblastoma","volume":"18","author":"Balaguer","year":"2023","journal-title":"Target Oncol"},{"key":"B31","unstructured":"Information on the pending collection of drug approval documents\n          \n          \n          \n          2021"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765578\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T05:22:54Z","timestamp":1770614574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1765578\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1765578"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1765578","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"article-number":"1765578"}}